Kolexia
Coquan Elodie Oncologie médicale
Coquan Elodie
Oncologie médicale
Centre François-Baclesse
Caen, France
102 Activités
139 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Néphrocarcinome Tumeurs de la prostate Tumeurs de la vessie urinaire Tumeurs de l'ovaire Tumeurs du rein Hypertension artérielle Carcinome épithélial de l'ovaire Carcinome transitionnel

Collaborateurs

Voir plus
Joly Florence
Joly Florence
Hôpital Côte de Nacre, Caen, France
Meriaux Emeline
Meriaux Emeline
Centre François-Baclesse, Caen, France
Allouache Nedjla
Allouache Nedjla
Centre François-Baclesse, Caen, France
Brachet Pierre-Emmanuel
Brachet Pierre-Emmanuel
Centre François-Baclesse, Caen, France

Industries

Voir plus
Janssen
26 collaboration(s)
Dernière en 2023
MSD
19 collaboration(s)
Dernière en 2023
Ipsen
16 collaboration(s)
Dernière en 2023
AstraZeneca
14 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.
Therapeutic advances in urology   28 février 2024
HERO: HRD Tests for Ovarian cancER
Essai Clinique (Centre François-Baclesse)   19 février 2024
First-in-human Phase I to Evaluate PEP-010 as Single Agent and in Combination With Paclitaxel or With Gemcitabine (CleverPeptide): Dose Escalation, First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of PEP-010, Administered as Single Agent and in Combination With Paclitaxel or With Gemcitabine in Patients With Metastatic Solid Cancer
Essai Clinique (Institut Curie)   15 février 2024
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley): A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)
Essai Clinique (Emd Serono)   05 février 2024
OLA-TMZ-RTE-01: Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
Essai Clinique (Centre François-Baclesse)   02 janvier 2024
21P Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE)
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
180P Immunogenomic profiling of the randomized NeoPembrOv clinical trial reveals the VEGFR2 angiogenic axis as a promising actionable target to overcome immunoresistance of high-grade ovarian carcinomas
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
752P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
2406P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma of the penis: Subgroup analysis of the PEVOsq basket trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
CHIVA: Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023